Erasca, Inc. (ERAS) Income Statement

The absence of any revenue line in the data confirms a clinical-stage profile where growth is not yet measurable. The only variability appears in non-operating items, such as the $183.4M net loss in 2026Q1, which likely reflects a one-time impairment or non-cash charge rather than operational momentum. Investors should monitor pipeline readouts for ERAS-007 and ERAS-801 as the sole potential catalysts for future revenue inflection.

With no COGS or revenue, traditional margin analysis is inapplicable; the negative gross profit in quarters like 2026Q1 (-$723K) likely stems from immaterial cost of goods related to clinical supplies or abandoned inventory. The persistent operating losses, ranging from -$32.6M to -$67.8M, underscore a high fixed-cost structure dominated by R&D. Margin improvement is structurally impossible until commercialization, making cash burn the more relevant profitability proxy.

The R&D line is the primary driver of operating losses, with quarterly spending fluctuating between $21.2M and $35.9M, reflecting variable trial activity and potential one-time costs. SG&A has remained relatively stable in the $8.8M-$12.2M range, suggesting disciplined overhead management, but the lack of revenue means any increase in R&D directly widens operating losses. This implies that the company is intentionally scaling clinical investment ahead of any potential revenue, a typical but risky strategy for a pre-commercial biotech.

The escalation in R&D from $21.2M in 2025Q2 to $35.9M in 2026Q2 suggests expanded clinical trial activity, likely for combination studies, which increases the burn rate. SG&A remains a secondary but stable cost, indicating no significant overhead creep. The high fixed-cost nature of clinical development means that any trial delays or expansions will directly impact the cash runway, which is currently estimated at under 12 months given the $73.8M cash balance.

This outlier quarter distorts the trailing twelve-month loss profile and may indicate a write-down of in-process R&D or a change in fair value of equity investments. The subsequent recovery to a $44.1M loss in 2026Q2 suggests the charge was non-recurring, but it also highlights the volatility inherent in biotech earnings. The lasting impact is a reduced book value and potential investor skepticism about the quality of reported losses, warranting a closer look at the cash flow statement for actual burn.